Sarepta Therapeutics (SRPT) shares plummeted 5.16% during intraday trading on Friday, reflecting significant negative sentiment toward the biopharmaceutical company.
The sharp decline followed news that Wells Fargo analyst Yanan Zhu lowered the firm's price target on Sarepta to $38 from $45, representing a substantial downward revision. While maintaining an Overweight rating on the shares, the reduced target price suggests concerns about the company's valuation or near-term prospects.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments